ADC Therapeutics SA (ADCT)
1.44
-0.16
(-10.00%)
USD |
NYSE |
Oct 23, 16:00
1.44
0.00 (0.00%)
After-Hours: 20:00
ADC Therapeutics Enterprise Value : 81.97M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 81.97M |
| October 22, 2026 | 102.36M |
| October 21, 2026 | 89.61M |
| October 20, 2026 | 92.16M |
| October 19, 2026 | 81.97M |
| October 16, 2026 | 76.87M |
| October 15, 2026 | 88.34M |
| October 14, 2026 | 83.24M |
| October 13, 2026 | 115.10M |
| October 12, 2026 | 135.49M |
| October 09, 2026 | 118.92M |
| October 08, 2026 | 101.08M |
| October 07, 2026 | 79.42M |
| October 06, 2026 | 60.30M |
| October 05, 2026 | 55.20M |
| October 02, 2026 | 42.46M |
| October 01, 2026 | 36.09M |
| September 30, 2026 | 53.93M |
| September 29, 2026 | 55.20M |
| September 28, 2026 | 59.03M |
| September 25, 2026 | 60.30M |
| September 24, 2026 | 62.85M |
| September 23, 2026 | 65.40M |
| September 22, 2026 | 55.20M |
| September 21, 2026 | 41.19M |
| Date | Value |
|---|---|
| September 18, 2026 | 32.27M |
| September 17, 2026 | 33.54M |
| September 16, 2026 | 32.27M |
| September 15, 2026 | 37.36M |
| September 14, 2026 | 39.91M |
| September 11, 2026 | 34.81M |
| September 10, 2026 | 39.91M |
| September 09, 2026 | 53.93M |
| September 08, 2026 | 64.13M |
| September 04, 2026 | 71.77M |
| September 03, 2026 | 66.67M |
| September 02, 2026 | 66.67M |
| September 01, 2026 | 56.48M |
| August 31, 2026 | 47.56M |
| August 28, 2026 | 43.74M |
| August 27, 2026 | 41.19M |
| August 26, 2026 | 32.27M |
| August 25, 2026 | 30.99M |
| August 24, 2026 | 21.45M |
| August 21, 2026 | 25.46M |
| August 20, 2026 | 20.81M |
| August 19, 2026 | 30.99M |
| August 18, 2026 | 29.72M |
| August 17, 2026 | 38.64M |
| August 14, 2026 | 27.17M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | 36.13B |
| AC Immune SA | 132.13M |
| CRISPR Therapeutics AG | 3.193B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.56M |
| Revenue (Quarterly) | 19.25M |
| Total Expenses (Quarterly) | 35.81M |
| EPS Diluted (Quarterly) | -0.1069 |
| Gross Profit Margin (Quarterly) | 87.80% |
| Profit Margin (Quarterly) | -86.06% |
| Earnings Yield | -46.08% |
| Normalized Earnings Yield | -57.45 |